FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366398423> ?p ?o ?g. }

• W4366398423 endingPage "101217" @default.
• W4366398423 startingPage "101217" @default.
• W4366398423 abstract "The results of the monarchE trial1Johnston S.R.D. Harbeck N. Hegg R. et al.Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE).J Clin Oncol. 2020; 38: 3987-3998Crossref PubMed Scopus (344) Google Scholar established a new standard of care for the adjuvant treatment of early high-risk hormone receptor (HR)-positive, HER2-negative breast cancer. Adding abemaciclib to adjuvant endocrine therapy reduced the risk of developing an invasive disease-free survival event by 30% and experiencing distant relapse by 31%, at 3 years. On these bases, the European Medicines Agency (EMA) approved the use of abemaciclib for the adjuvant treatment of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.2European Medicines AgencyAssessment report: Verzenios; 2022.https://www.ema.europa.eu/en/documents/variation-report/verzenios-h-c-004302-ii-0013-epar-assessment-report-variation_en.pdfDate accessed: April 5, 2023Google Scholar ‘High-risk’ has been defined according to the inclusion criteria of cohort 1 of the monarchE trial: either four or more positive axillary lymph nodes or one or three positive lymph nodes and at least tumor size ≥5 cm or histological grade 3. Nevertheless, this indication could be easily misinterpreted. It is crucial to underline that the EMA indication of abemaciclib extends to patients with cytological tumor involvement at the time of initial diagnosis and that meet at least one of the following criteria: grade 3 or pathological primary invasive tumor size ≥5 cm. Moreover, tumor size in patients who receive neoadjuvant therapy can be evaluated on breast imaging, and importantly, patients with multifocal/multicentric tumors may be eligible based on the addition of diameters of the individual lesions. In a recent research study, nodal pathological complete response (pCR) rate after neoadjuvant chemotherapy (NAC) in luminal breast cancer was 24.8%.3Boughey J.C. Hoskin T.L. Goetz M.P. Neoadjuvant chemotherapy and nodal response rates in luminal breast cancer: effects of age and tumor Ki67.Ann Surg Oncol. 2022; 29: 5747-5756Crossref PubMed Scopus (3) Google Scholar Therefore almost one out of four patients diagnosed with node-positive luminal breast cancer treated with NAC potentially achieve nodal pCR and could be erroneously excluded by adjuvant treatment with abemaciclib. Overall, 36% of the monarchE intent-to-treat population received NAC, but documentation of nodal pCR after NAC was not collected, and thus only pCR in the breast is reported.4Martin M. Hegg R. Kim S.B. et al.Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).J Clin Oncol. 2021; 39: 517Crossref Google Scholar These considerations highlight the need for a proper clinical staging on locoregional lymph nodes at the diagnosis of disease and the importance of looking for cytological confirmation of all suspect nodes. All these additional criteria shall be stressed and spread to avoid missing any patient that could benefit from an effective adjuvant treatment and spare patients from unnecessary axillary dissections. None declared." @default.
• W4366398423 created "2023-04-21" @default.
• W4366398423 creator A5020324515 @default.
• W4366398423 creator A5066082415 @default.
• W4366398423 date "2023-06-01" @default.
• W4366398423 modified "2023-09-25" @default.
• W4366398423 title "Are you treating ypN0 patient with adjuvant abemaciclib?" @default.
• W4366398423 cites W3170182733 @default.
• W4366398423 cites W4206349107 @default.
• W4366398423 cites W4280581867 @default.
• W4366398423 doi "https://doi.org/10.1016/j.esmoop.2023.101217" @default.
• W4366398423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37079950" @default.
• W4366398423 hasPublicationYear "2023" @default.
• W4366398423 type Work @default.
• W4366398423 citedByCount "0" @default.
• W4366398423 crossrefType "journal-article" @default.
• W4366398423 hasAuthorship W4366398423A5020324515 @default.
• W4366398423 hasAuthorship W4366398423A5066082415 @default.
• W4366398423 hasBestOaLocation W43663984231 @default.
• W4366398423 hasConcept C121608353 @default.
• W4366398423 hasConcept C126322002 @default.
• W4366398423 hasConcept C143998085 @default.
• W4366398423 hasConcept C2777649267 @default.
• W4366398423 hasConcept C2777863537 @default.
• W4366398423 hasConcept C2777982462 @default.
• W4366398423 hasConcept C530470458 @default.
• W4366398423 hasConcept C71924100 @default.
• W4366398423 hasConcept C72563966 @default.
• W4366398423 hasConceptScore W4366398423C121608353 @default.
• W4366398423 hasConceptScore W4366398423C126322002 @default.
• W4366398423 hasConceptScore W4366398423C143998085 @default.
• W4366398423 hasConceptScore W4366398423C2777649267 @default.
• W4366398423 hasConceptScore W4366398423C2777863537 @default.
• W4366398423 hasConceptScore W4366398423C2777982462 @default.
• W4366398423 hasConceptScore W4366398423C530470458 @default.
• W4366398423 hasConceptScore W4366398423C71924100 @default.
• W4366398423 hasConceptScore W4366398423C72563966 @default.
• W4366398423 hasFunder F4320311022 @default.
• W4366398423 hasIssue "3" @default.
• W4366398423 hasLocation W43663984231 @default.
• W4366398423 hasLocation W43663984232 @default.
• W4366398423 hasLocation W43663984233 @default.
• W4366398423 hasOpenAccess W4366398423 @default.
• W4366398423 hasPrimaryLocation W43663984231 @default.
• W4366398423 hasRelatedWork W1594300427 @default.
• W4366398423 hasRelatedWork W2051447115 @default.
• W4366398423 hasRelatedWork W2054423421 @default.
• W4366398423 hasRelatedWork W2096393323 @default.
• W4366398423 hasRelatedWork W2224319365 @default.
• W4366398423 hasRelatedWork W2263577673 @default.
• W4366398423 hasRelatedWork W2414195948 @default.
• W4366398423 hasRelatedWork W4285804722 @default.
• W4366398423 hasRelatedWork W4322770500 @default.
• W4366398423 hasRelatedWork W4367319693 @default.
• W4366398423 hasVolume "8" @default.
• W4366398423 isParatext "false" @default.
• W4366398423 isRetracted "false" @default.
• W4366398423 workType "article" @default.